Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI
Subjects
More information
Scope and Contents
Contents
Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient’s response to androgen ablation therapy is variable, and 20–30% of PCa...
Alternative Titles
Full title
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_72c710ec62324a2f9ab9a446099b76cd
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_72c710ec62324a2f9ab9a446099b76cd
Other Identifiers
ISSN
2073-4409
E-ISSN
2073-4409
DOI
10.3390/cells9122653
